ANDA 62772, held by HQ Specialty Pharma. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 62772 (Ampicillin Sodium), held by HQ Specialty Pharma, was first approved by FDA on Apr 15, 1993, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by S. pneumoniae, Staphylococcus aureus (penicillinase and non-penicillinase producing), H. influenzae and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 1993 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 125MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| May 1, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 31, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 23, 2007 | Supplement 6Labeling | Approved | None posted |
| Feb 28, 2007 | Supplement 4Labeling | Approved | None posted |
| Feb 14, 1994 | Supplement 1Manufacturing | Approved | None posted |
| Nov 5, 1993 | Supplement 2Manufacturing | Approved | None posted |
| Apr 15, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters